TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12618568

Group type: EXPERIMENTAL
Intervention: rest and cuff occlusion with relaxation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: relaxation alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: relaxation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PECO with relaxation
Number of subjects: 16

Group type: COMPARATOR
Intervention: PECO
Number of subjects: 16
Study: 10229137

Group type: EXPERIMENTAL
Intervention: Manual oscillation technique applied at T12 and L4 for 12 minutes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Resting
Number of subjects: 30
Study: 8764423

Group type: EXPERIMENTAL
Intervention: Macaine (Keatings)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Regibloc (Intramed)
Number of subjects: 104
Study: 1906935

Group type: COMPARATOR
Intervention: Gold sodium thiomalate (GSTM) 50 mg intramuscularly for 6 months
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg intramuscularly for 6 months
Number of subjects: 57
Study: 6600579

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (40 mg/kg/day every six hours for seven days)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate
Number of subjects: 27
Study: 30165750

Group type: EXPERIMENTAL
Intervention: Clemastine 2 mg (1 mg/ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saline 2 ml)
Number of subjects: 20
Study: 28296735

Group type: EXPERIMENTAL
Intervention: Remifentanil (infused at 0.1 μg/kg/min with demand boluses of 0.1 μg/kg)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144

Group type: COMPARATOR
Intervention: Remifentanil and Placebo
Number of subjects: 144
Study: 27012255

Group type: EXPERIMENTAL
Intervention: Choice condition (parent training program options)
Number of subjects: 129

Group type: COMPARATOR
Intervention: No-choice condition (parent training program options)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: In-home treatment (preferred modality in choice condition)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Group and clinic modalities (across conditions)
Number of subjects: 129
Study: 24525810

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg daily)
Number of subjects: 601

Group type: COMPARATOR
Intervention: Reboxetine (4 mg twice daily)
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Citalopram and Reboxetine
Number of subjects: 601
Study: 22653993

Group type: EXPERIMENTAL
Intervention: RISE-95 test (ramp-incremental step-exercise test)
Number of subjects: 24
Study: 19682128

Group type: EXPERIMENTAL
Intervention: Participants in the trial
Number of subjects: 1105

Group type: COMPARATOR
Intervention: Nonresponding nonparticipants
Number of subjects: 1105
Study: 17973732

Group type: EXPERIMENTAL
Intervention: Intervention (noise assessments, educational sessions, mailed reminders with brochures, placement of hearing protection)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Comparison (no specific intervention mentioned)
Number of subjects: 25
Study: 15365306

Group type: EXPERIMENTAL
Intervention: Injectable naltrexone (400 mg, administered intramuscularly once every 28 days for 4 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo injection (matching to naltrexone, administered once every 28 days for 4 months)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Injectable naltrexone
Number of subjects: 30
Study: 11226444

Group type: EXPERIMENTAL
Intervention: Constant 17beta‐estradiol (E2), 1 mg, plus intermittent norgestimate (NGM) 90 microg (3 days off, 3 days on)
Number of subjects: 438

Group type: COMPARATOR
Intervention: E2 2 mg/norethisterone acetate (NETA) 1 mg
Number of subjects: 438
Study: 9678315

Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of Lewy body disease
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of Parkinson disease (PD)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of dementia with Lewy bodies (DLB)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Raters' results compared to primary neurologists
Number of subjects: 105
Study: 7986315

Group type: EXPERIMENTAL
Intervention: Fluvastatin 2.5 mg q.p.m.
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Fluvastatin 5 mg q.p.m.
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Fluvastatin 10 mg q.p.m.
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg q.p.m.
Number of subjects: 429

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study: 2532801

Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (27 Gy) combined with local microwave hyperthermia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative irradiation (27 Gy) alone
Number of subjects: 0
Study: 30982442

Group type: EXPERIMENTAL
Intervention: Astaxanthin supplementation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High dose astaxanthin (≥20 mg/day)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low dose astaxanthin (<20 mg/day)
Number of subjects: 9
Study: 31081140

Group type: EXPERIMENTAL
Intervention: Intrauterine tamponade
Number of subjects: 20060

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 20060

Group type: EXPERIMENTAL
Intervention: Laparotomy
Number of subjects: 20060
Study: 28043661

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation (MV)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 219
Study: 26003264

Group type: EXPERIMENTAL
Intervention: Psychological intervention (group sessions, once a week for 5 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual treatment (including dietary advice)
Number of subjects: 54
Study: 23305646

Group type: EXPERIMENTAL
Intervention: GcgR agonist
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Natural glucagon injection
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: GcgR activation in WT mice
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: GcgR activation in FGF21 knockout mice
Number of subjects: 2
Study: 21501887

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 30
Study: 18274899

Group type: EXPERIMENTAL
Intervention: BIS-guided propofol sedation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard propofol sedation
Number of subjects: 44
Study: 16446191

Group type: EXPERIMENTAL
Intervention: Biodegradable restrictor
Number of subjects: 32

Group type: COMPARATOR
Intervention: UHMWPE restrictor
Number of subjects: 32
Study: 12867397

Group type: EXPERIMENTAL
Intervention: Artisan Hyperopia phakic intraocular lens (IOL; model 203W; Ophtec, Groningen, The Netherlands) implanted in patients with hypermetropia.
Number of subjects: 26
Study: 10390394

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP), 1,000 micrograms twice a day
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD), 800 micrograms twice a day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP), 200 micrograms twice a day
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD), 200 micrograms twice a day
Number of subjects: 23
Study: 8656545

Group type: EXPERIMENTAL
Intervention: Intranasal lidocaine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 81
Study: 2067759

Group type: EXPERIMENTAL
Intervention: Magnesium pyrrolidone carboxylic acid (360 mg Mg) administered three times a day from the 15th day of the menstrual cycle to the onset of menstrual flow
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo administered three times a day from the 15th day of the menstrual cycle to the onset of menstrual flow
Number of subjects: 32
Study: 6336937

Group type: EXPERIMENTAL
Intervention: Intramuscular cephaloridine (three 1-g perioperative doses)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Oral erythromycin base and neomycin sulfate (three 1-g preoperative doses)
Number of subjects: 123
Study: 31560027

Group type: EXPERIMENTAL
Intervention: Progressive resistance training 3 days/week for 12 weeks
Number of subjects: 70
Study: 29596045

Group type: EXPERIMENTAL
Intervention: Manual‐assisted face‐to‐face Positive Behaviour Support (PBS) training
Number of subjects: 246

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: PBS training
Number of subjects: 246
Study: 28051337

Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT) for 12 sessions (n=40)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Waitlist (WL) condition (n=44)
Number of subjects: 84
Study: 26695667

Group type: EXPERIMENTAL
Intervention: PCT group (antibiotic therapy guided by serum procalcitonin)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Control group (standard therapy according to clinical guidance)
Number of subjects: 396
Study: 24252418

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (VAS)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (VAS) for males
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (VAS) for females
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study: 21255035

Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 400

Group type: COMPARATOR
Intervention: OAT
Number of subjects: 400
Study: 18448301

Group type: EXPERIMENTAL
Intervention: Navigator setting under the left hepatic lobe
Number of subjects: 50

Group type: COMPARATOR
Intervention: Navigator setting on the right diaphragm
Number of subjects: 50
Study: 16788393

Group type: EXPERIMENTAL
Intervention: High-frequency cranial electrostimulation, 30 mins/day, 5 days/week, for 6 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 21
Study: 12671541

Group type: EXPERIMENTAL
Intervention: Isoflavone supplement (100 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11269917

Group type: EXPERIMENTAL
Intervention: EMLA cream (2.5% lidocaine and 2.5% prilocaine in oil emulsion) applied 2 hours prior to microneurography
Number of subjects: 10

Group type: COMPARATOR
Intervention: Aqueous placebo cream applied 2 hours prior to microneurography
Number of subjects: 10
Study: 9408797

Group type: EXPERIMENTAL
Intervention: Dichotic listening under divided attention condition
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dichotic listening under focused attention condition 1
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dichotic listening under focused attention condition 2
Number of subjects: 16
Study: 8147088

Group type: EXPERIMENTAL
Intervention: Complex physical therapy (CPT) including special lymphatic massage after surgical reconstruction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex physical therapy (CPT)
Number of subjects: 0
Study: 3524119

Group type: EXPERIMENTAL
Intervention: Desenkephalin-gamma-endorphin (3 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ceruletide (40 micrograms)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 29055287

Group type: EXPERIMENTAL
Intervention: 7630 (Pelargonium extract)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 27511342

Group type: EXPERIMENTAL
Intervention: Transtheoretical model-based individual counseling and training (5 interviews over 6 months)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 77
Study: 24630510

Group type: EXPERIMENTAL
Intervention: Cholecystectomy after endoscopic sphincterotomy (ES)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Wait-and-see policy (conservative management) after ES
Number of subjects: 162
Study: 23946347

Group type: EXPERIMENTAL
Intervention: 3.3 g/d oat β-glucans for 3 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 3.3 g/d oat β-glucans
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no β-glucans)
Number of subjects: 14
Study: 21118514

Group type: EXPERIMENTAL
Intervention: Intensive education on lifestyle improvement related to type 2 diabetes by registered dietitians in clinics.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard advice on glycemic control by registered dietitians.
Number of subjects: 200
Study: 18179714

Group type: EXPERIMENTAL
Intervention: Usual care plus the use of the Australian Medical Sheepskin as an overlay on the mattress
Number of subjects: 750

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 750
Study: 16606423

Group type: EXPERIMENTAL
Intervention: Rural residence
Number of subjects: 1510

Group type: EXPERIMENTAL
Intervention: Rural residence (after controlling for screening tests)
Number of subjects: 1510

Group type: COMPARATOR
Intervention: Colorectal cancer screening rates
Number of subjects: 1510
Study: 12599028

Group type: EXPERIMENTAL
Intervention: Closed suction drains
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no suction drains)
Number of subjects: 0
Study: 10942739

Group type: EXPERIMENTAL
Intervention: Lotrafiban 5 mg
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Lotrafiban 100 mg
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Lotrafiban (all doses)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study: 8769625

Group type: EXPERIMENTAL
Intervention: Pentoxifylline administered intravenously 90 min before penicillin injection
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no pentoxifylline)
Number of subjects: 15
Study: 1408297

Group type: EXPERIMENTAL
Intervention: Self-administered treatment
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Therapist-delivered treatment
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 87
Study: 3532771

Group type: EXPERIMENTAL
Intervention: Dialysate calcium of 2.5 mEq/L
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dialysate calcium of 3.5 mEq/L
Number of subjects: 20
Study: 31636023

Group type: EXPERIMENTAL
Intervention: Galvanic vestibular stimulation (GVS) - left-anodal and right-anodal
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Optokinetic vestibular stimulation (OKS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham GVS
Number of subjects: 16

Group type: COMPARATOR
Intervention: Distraction task
Number of subjects: 16
Study: 29749113

Group type: EXPERIMENTAL
Intervention: Initial anti-viral therapy (valaciclovir 500-1000 mg 1-3 times daily, aciclovir 200-400 mg 1-5 times daily, topical aciclovir 2-5 times daily, topical trifluorothymidine two hourly or as needed)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Evidence-based anti-viral therapy
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Indication and dose of prescribed anti-virals
Number of subjects: 296
Study: 26248652

Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (37.5 mg), twice daily, through last dose of oxaliplatin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 24434303

Group type: EXPERIMENTAL
Intervention: Training course on difficult airway management
Number of subjects: 27
Study: 21208597

Group type: EXPERIMENTAL
Intervention: Zolpidem extended-release 12.5 mg/night
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Zolpidem extended-release/escitalopram
Number of subjects: 385

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study: 16134315

Group type: EXPERIMENTAL
Intervention: Rapid cardiac 31P-MRS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects (n = 13)
Number of subjects: 20
Study: 12269458

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 1,450 ppmF (Colgate Great Regular Flavour)
Number of subjects: 3731

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 440 ppmF (Colgate 0‐6 Gel)
Number of subjects: 3731

Group type: COMPARATOR
Intervention: Control group (no fluoride toothpaste provided)
Number of subjects: 3731
Study: 9494149

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 microg four times daily)
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole (maintenance therapy)
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 microg twice daily, maintenance therapy)
Number of subjects: 935

Group type: COMPARATOR
Intervention: Placebo (maintenance therapy)
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 935
Study: 8033494

Group type: EXPERIMENTAL
Intervention: Torsemide 50 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Torsemide 100 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Torsemide 200 mg
Number of subjects: 16
Study: 2692091

Group type: EXPERIMENTAL
Intervention: Transtracheal oxygen delivery (n = 22)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Usual delivery of O2 by nasal cannula or face mask (n = 21)
Number of subjects: 43
Study: 789827

Group type: EXPERIMENTAL
Intervention: Chymopapain
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 12366873

Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe) 800 mg in 250 ml isotonic solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo 250 ml isotonic solution
Number of subjects: 10
Study: 29796649

Group type: EXPERIMENTAL
Intervention: Letter + Reminder Call (RC arm)
Number of subjects: 30162

Group type: EXPERIMENTAL
Intervention: Two Letters + Counseling Call (CC arm)
Number of subjects: 30162

Group type: EXPERIMENTAL
Intervention: Reminder Letter Only (LO arm)
Number of subjects: 30162

Group type: COMPARATOR
Intervention: Incremental cost for RC arm compared to LO arm
Number of subjects: 30162
Study: 29804416

Group type: EXPERIMENTAL
Intervention: Mild hypothermia therapy (maintained at 35±1 ℃ for 5-7 days)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Routine treatment (RT) including bloody cerebrospinal fluid drainage, spasmolysis, 3H treatment, etc.
Number of subjects: 62
Study: 27909121

Group type: EXPERIMENTAL
Intervention: X3 HXLPE liner
Number of subjects: 15
Study: 24832638

Group type: EXPERIMENTAL
Intervention: Paclitaxel drug‐eluting balloons (pDEB) plus bare metal stent (BMS)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Drug-eluting stents (DES)
Number of subjects: 108
Study: 22396515

Group type: COMPARATOR
Intervention: Testosterone enanthate 50 mg/wk + placebo
Number of subjects: 139

Group type: COMPARATOR
Intervention: Testosterone enanthate 125 mg/wk + placebo
Number of subjects: 139

Group type: COMPARATOR
Intervention: Testosterone enanthate 300 mg/wk + placebo
Number of subjects: 139

Group type: COMPARATOR
Intervention: Testosterone enanthate 600 mg/wk + placebo
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 50 mg/wk + dutasteride
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 125 mg/wk + dutasteride
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 300 mg/wk + dutasteride
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 600 mg/wk + dutasteride
Number of subjects: 139
Study: 20931531

Group type: EXPERIMENTAL
Intervention: MQ‐LCR technique for detecting mutations
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: MQ‐LCR technique
Number of subjects: 128
Study: 18551213

Group type: EXPERIMENTAL
Intervention: Cementation with adhesive bonding (group ADH) after pretreatment of the tooth and crown.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cementation with universal adhesive resin cement without pretreatment (group HYB).
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Conventional cementation with zinc phosphate cement without pretreatment (group ZOP).
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cementation techniques comparison for leakage values.
Number of subjects: 48
Study: 16109551

Group type: EXPERIMENTAL
Intervention: ACEI (ramipril starting dose of 2.5 mg/d gradually reaching 5 mg/d)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: ARB (irbesartan with gradual increase of doses till reaching maximum daily dose of 150 mg)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 145
Study: 12207842

Group type: EXPERIMENTAL
Intervention: Health and nutrition education programme (IG)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 602
Study: 9527092

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 48
Study: 7638210

Group type: EXPERIMENTAL
Intervention: HHV-6 presence in MS cases
Number of subjects: 86

Group type: COMPARATOR
Intervention: HHV-6 presence in controls
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Nuclear staining of oligodendrocytes in MS cases
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Cytoplasmic staining of neurons in MS cases
Number of subjects: 86

Group type: COMPARATOR
Intervention: Neurons expressing HHV-6 in controls
Number of subjects: 86
Study: 2775616

Group type: EXPERIMENTAL
Intervention: Halofantrine 250 mg fasting
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Halofantrine 250 mg after fatty meal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Halofantrine 500 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Halofantrine 1000 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Halofantrine 250 mg fasting vs 250 mg after fatty meal
Number of subjects: 6

Group type: COMPARATOR
Intervention: Halofantrine 500 mg vs 1000 mg
Number of subjects: 6
Study: 327746

Group type: EXPERIMENTAL
Intervention: Pizotifen
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Divascan
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31866194

Group type: EXPERIMENTAL
Intervention: Residents sitting at the bedside during rounds
Number of subjects: 347

Group type: COMPARATOR
Intervention: Residents standing at the bedside during rounds
Number of subjects: 347
Study: 30592549

Group type: EXPERIMENTAL
Intervention: Oral insulin tregopil (IN‐105)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28415636

Group type: EXPERIMENTAL
Intervention: Leflunomide + low-dose corticosteroid
Number of subjects: 85

Group type: COMPARATOR
Intervention: Full-dose corticosteroid
Number of subjects: 85